FR940817-2-00215 FR940817-2-00113 Final Report: Principles of Neurotoxicology Risk Assessment Contents 1. Introduction 1.1. Background 1.2. Purpose of This Report 1.3. Context of This Report 1.4. Content of This Report 2. Overview of Neurotoxicology 2.1. Scope of the Problem 2.1.1. Introduction 2.1.2. Examples of Neurotoxicity and Incidents of Exposure 2.1.3. Federal Response 2.1.3.1. Food and Drug Administration 2.1.3.2. Occupational Safety and Health Administration 2.1.3.3. National Institute for Occupational Safety and Health 2.1.3.4. Environmental Protection Agency 2.1.3.5. Consumer Product Safety Commission 2.1.3.6. Agency for Toxic Substances and Disease Registry 2.2. Basic Toxicological Considerations for Neurotoxicity 2.2.1. Basic Toxicological Principles 2.2.2. Basic Neurotoxicological Principles 2.3. Basic Neurobiological Principles 2.3.1. Structure of the Nervous System 2.3.2. Transport Processes 2.3.3. Ionic Balance 2.3.4. Neurotransmission 2.4. Types of Effects on the Nervous System 2.5. Special Considerations 2.5.1. Susceptible Populations 2.5.2. Blood-Brain and Blood-Nerve Barriers 2.5.3. Metabolism 2.5.4. Limited Regenerative Ability 3. Methods for Assessing Human Neurotoxicity 3.1. Introduction 3.2. Clinical Evaluation 3.2.1. Neurologic Evaluation 3.2.2. Neuropsychological Testing 3.2.3 Applicability of Clinical Methods to Neurotoxicology Risk Assessment 3.3. Current Neurotoxicity Testing Methods 3.3.1. Neurobehavioral Methods 3.3.1.1. Test Batteries 3.3.1.2. Investigator-Administered Test Batteries 3.3.1.3. Computerized Test Batteries 3.3.2. Neurophysiologic Methods 3.3.3. Neurochemical Methods 3.3.4. Imaging Techniques 3.3.5. Neuropathologic Methods 3.3.6. Self-Report Assessment Methods 3.3.6.1. Mood Scales 3.3.6.2. Personality Scales 3.4. Approaches to Neurotoxicity Assessment 3.4.1. Epidemiologic Studies 3.4.1.1. Case Reports 3.4.1.2. Cross-Sectional Studies 3.4.1.3. Case-Control (Retrospective) Studies 3.4.1.4. Prospective (Cohort, Followup) Studies 3.4.2. Human Laboratory Exposure Studies 3.4.2.1. Methodologic Aspects 3.4.2.2. Human Subject Selection Factors 3.4.2.3. Exposure Conditions and Chemical Classes 3.4.2.4. Test Methods 3.4.2.5. Controls 3.4.2.6. Ethical Issues 3.5. Assessment of Developmental Neurotoxicity 3.5.1. Developmental Deficits 3.5.2. Methodologic Considerations 3.6. Issues in Human Neurotoxicology Test Methods 3.6.1. Risk Assessment Criteria for Neurobehavioral Test Methods 3.6.1.1. Sensitivity 3.6.1.2. Specificity 3.6.1.3. Reliability and Validity 3.6.1.4. Dose Response 3.6.1.5. Structure-Activity 3.6.2. Other Considerations in Risk Assessment 3.6.2.1. Mechanisms of Action 3.6.2.2. Exposure Duration 3.6.2.3. Time-Dependent Effects 3.6.2.4. Multiple Exposures 3.6.2.5. Generalizability and Individual Differences 3.6.2.6. Veracity of Neurobehavioral Test Results 3.6.3. Cross-Species Extrapolation 4. Methods to Assess Animal Neurotoxicity 4.1. Introduction 4.1.1. Role of Animal Models 4.1.2. Validity of Animal Models 4.1.3. Special Considerations in Animal Models 4.1.3.1. Susceptible Populations 4.1.3.2. Dosing Scenario 4.1.3.3. Other Factors 4.1.3.4. Statistical Considerations 4.2. Tiered Testing in Neurotoxicology 4.2.1. Type of Test 4.2.2. Dosing Regimen 4.3. Endpoints of Neurotoxicity 4.3.1. Introduction 4.3.2. Behavioral Endpoints 4.3.2.1. Functional Observational Batteries 4.3.2.2. Motor Activity 4.3.2.3. Neuromotor Function 4.3.2.4. Sensory Function 4.3.2.5. Learning and Memory 4.3.2.6. Schedule-Controlled Behavior 4.3.3. Neurophysiological Endpoints of Neurotoxicity 4.3.3.1. Nerve Conduction Studies 4.3.3.2. Sensory Evoked Potentials 4.3.3.3. Convulsions 4.3.3.4. Electroencephalography 4.3.3.5. Electromyography 4.3.3.6. Spinal Reflex Excitability 4.3.4. Neurochemical Endpoints of Neurotoxicity 4.3.5. Structural Endpoints of Neurotoxicity 4.3.6. Developmental Neurotoxicity 4.3.7. Physiological and Neuroendocrine Endpoints 4.3.8. Other Considerations 4.3.8.1. Structure-Activity Relationship 4.3.8.2. In Vitro Methods 5. Neurotoxicology Risk Assessment 5.1. Introduction 5.2. The Risk Assessment Process 5.2.1. Hazard Identification 5.2.1.1. Human Studies 5.2.1.2. Animal Studies 5.2.1.3. Special Issues 5.2.2. Dose-Response Assessment 5.2.3. Exposure Assessment 5.2.4. Risk Characterization 5.3. Generic Assumptions and Uncertainty Reduction 6. General Summary 7. References Tables 1&hyph;1. Major Regulatory Agencies 1&hyph;2. Authorities for Toxicity Testing 2&hyph;1. Human Neurotoxic Exposures 3&hyph;1. Neurobehavioral Methods 4&hyph;1. Examples of Potential Endpoints of Neurotoxicity 4&hyph;2. Examples of Specialized Tests to Measure Neurotoxicity 4&hyph;3. Summary of Measures in the Functional Observational Battery and the Type of Data Produced by Each 4&hyph;4. Neurotoxicants With Known Neurochemical Mechanisms 4&hyph;5. Examples of Known Neuropathic Agents 4&hyph;6. Partial List of Agents Believed to Have Developmental Neurotoxicity 5&hyph;1. General Assumptions That Underlie Traditional Risk Assessments
